Emerging drugs to treat alcoholism (Q37766239)

22 August 2017

1 reference

title

Emerging drugs to treat alcoholism (English)

1 reference

22 August 2017

0 references

Michael Soyka

1

1 reference

PubMed ID

20560783

22 August 2017

Susanne Rösner

series ordinal

2

1 reference

PubMed ID

20560783

22 August 2017

language of work or name

English

0 references

publication date

19 June 2010

1 reference

Expert Opinion on Emerging Drugs

22 August 2017

1 reference

22 August 2017

15

1 reference

22 August 2017

4

1 reference

22 August 2017

695-711

1 reference

Cannabinoid receptor 1 blocker rimonabant (SR 141716) for treatment of alcohol dependence: results from a placebo-controlled, double-blind trial

22 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.500811

Neuropharmacology of alcohol addiction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.500811

The neurocircuitry of addiction: an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.500811

Treatment of depression in patients with alcohol or other drug dependence: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.500811

Sertraline treatment of co-occurring alcohol dependence and major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.500811

Pharmacotherapy of schizophrenia with comorbid substance use disorder--reviewing the evidence and clinical recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.500811

Acamprosate: recent findings and future research directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.500811

Acamprosate inhibits the binding and neurotoxic effects of trans-ACPD, suggesting a novel site of action at metabotropic glutamate receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.500811

Chronic acamprosate eliminates the alcohol deprivation effect while having limited effects on baseline responding for ethanol in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.500811

Effects of acute acamprosate and homotaurine on ethanol intake and ethanol-stimulated mesolimbic dopamine release.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.500811

Central effects of acamprosate: part 2. Acamprosate modifies the brain in-vivo proton magnetic resonance spectrum in healthy young male volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.500811

The clock gene Per2 influences the glutamatergic system and modulates alcohol consumption

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.500811

Acamprosate blocks the increase in dopamine extracellular levels in nucleus accumbens evoked by chemical stimulation of the ventral hippocampus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.500811

The dopamine hypothesis of reward: past and current status

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.500811

Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.500811

Effect of oral acamprosate on abstinence in patients with alcohol dependence in a double-blind, placebo-controlled trial: the role of patient motivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.500811

Acamprosate in Korean alcohol-dependent patients: a multi-centre, randomized, double-blind, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.500811

Naltrexone versus acamprosate in the treatment of alcohol dependence: A multi-centre, randomized, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.500811

Efficacy of acamprosate in the treatment of alcohol-dependent outpatients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.500811

Update on neuropharmacological treatments for alcoholism: scientific basis and clinical findings

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.500811

Efficacy of Naltrexone and Acamprosate for Alcoholism Treatment: A Meta-Analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.500811

Does acamprosate improve reduction of drinking as well as aiding abstinence?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.500811

The efficacy of acamprosate in the maintenance of abstinence in alcohol-dependent individuals: results of a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.500811

Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.500811

Predictors of acamprosate efficacy: results from a pooled analysis of seven European trials including 1485 alcohol-dependent patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.500811

Acamprosate supports abstinence, naltrexone prevents excessive drinking: evidence from a meta-analysis with unreported outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.500811

Endogenous opioids and addiction to alcohol and other drugs of abuse

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.500811

Endogenous opioid systems and alcohol addiction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.500811

Effect of naltrexone on alcohol "high" in alcoholics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.500811

Reward-motivated learning: mesolimbic activation precedes memory formation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.500811

Naltrexone blocks the post-shock increase of ethanol consumption

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.500811

Genetic differences in the rewarding and activating effects of morphine and ethanol

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.500811

Different roles of mu-, delta- and kappa-opioid receptors in ethanol-associated place preference in rats exposed to conditioned fear stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.500811

Effects of Naltrexone Alone and In Combination With Acamprosate on the Alcohol Deprivation Effect in Rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.500811

Evidence about the use of naltrexone and for different ways of using it in the treatment of alcoholism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.500811

Effects of opiate antagonist treatment on the alcohol deprivation effect in long-term ethanol-experienced rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.500811

Naltrexone in the treatment of alcohol dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.500811

Naltrexone, a relapse prevention maintenance treatment of alcohol dependence: a meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.500811

Naltrexone for the treatment of alcoholism: a meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.500811

A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.500811

An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.500811

Effects of long-term therapy with naltrexone on body weight in obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.500811

Narcotic withdrawal syndrome caused by naltrexone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.500811

Pharmacotherapy of alcohol use disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.500811

A rational approach to the pharmacotherapy of alcohol dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.500811

Why is disulfiram superior to acamprosate in the routine clinical setting? A retrospective long-term study in 353 alcohol-dependent patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.500811

Currently active and remitted alcohol dependence in a nationwide adult general population--results from the Finnish Health 2000 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.500811

Co-occurring DSM-IV drug abuse in DSM-IV drug dependence: results from the National Epidemiologic Survey on Alcohol and Related Conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.500811

Alcohol use disorders in EU countries and Norway: an overview of the epidemiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.500811

Co-occurrence of 12-month alcohol and drug use disorders and personality disorders in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.500811

Neuropharmacological treatments for alcoholism: scientific basis and clinical findings

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.500811

Pharmacological treatment of alcohol dependence: target symptoms and target mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.500811

Pharmacological management of alcohol withdrawal. A meta-analysis and evidence-based practice guideline. American Society of Addiction Medicine Working Group on Pharmacological Management of Alcohol Withdrawal

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.500811

Management of alcohol withdrawal delirium. An evidence-based practice guideline

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.500811

Alcoholism: allostasis and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.500811

Effect of the cannabinoid CB1 receptor antagonist SR-141716A on ethanol self-administration and ethanol-seeking behaviour in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.500811

GABA-benzodiazepine receptor function in alcohol dependence: a combined 11C-flumazenil PET and pharmacodynamic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.500811

Variations in GABRA2, encoding the alpha 2 subunit of the GABA(A) receptor, are associated with alcohol dependence and with brain oscillations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.500811

Allelic and haplotypic association of GABRA2 with alcohol dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.500811

Association of GABRG3 with alcohol dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.500811

Naltrexone depot for treatment of alcohol dependence: a multicenter, randomized, placebo-controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.500811

Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.500811

A pilot evaluation of the safety and tolerability of repeat dose administration of long-acting injectable naltrexone (Vivitrex) in patients with alcohol dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.500811

Effect of extended-release naltrexone (XR-NTX) on quality of life in alcohol-dependent patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.500811

Pharmacokinetics, safety, and tolerability of a depot formulation of naltrexone in alcoholics: an open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.500811

A double-blind, placebo-controlled study of oral nalmefene for alcohol dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.500811

Prolonged central mu-opioid receptor occupancy after single and repeated nalmefene dosing

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.500811

Nalmefene: safety and kinetics after single and multiple oral doses of a new opioid antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.500811

A multi-site dose ranging study of nalmefene in the treatment of alcohol dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.500811

A double-blind, placebo-controlled pilot study to evaluate the efficacy and safety of oral nalmefene HCl for alcohol dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.500811

Synthesis and pharmacological evaluation of 6-naltrexamine analogs for alcohol cessation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.500811

Review of topiramate: an antiepileptic for the treatment of alcohol dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.500811

GABA(B) receptor agonists for the treatment of drug addiction: a review of recent findings

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.500811

Baclofen antagonizes nicotine-, cocaine-, and morphine-induced dopamine release in the nucleus accumbens of rat

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.500811

Ethanol potentiation of GABAergic synaptic transmission may be self-limiting: role of presynaptic GABA(B) receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.500811

Role of the GABA(B) receptor system in alcoholism and stress: focus on clinical studies and treatment perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.500811

Role of the GABA(B) receptor in alcohol-seeking and drinking behavior

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.500811

Effectiveness and safety of baclofen in the treatment of alcohol dependent patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.500811

Suppression by baclofen of the stimulation of alcohol intake induced by morphine and WIN 55,212-2 in alcohol-preferring rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.500811

Opposite changes in the mesolimbic dopamine metabolism in the nerve terminal and cell body sites induced by locally infused baclofen in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.500811

The GABA(B) receptor agonists baclofen and CGP 44532 prevent acquisition of alcohol drinking behaviour in alcohol-preferring rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.500811

Suppression by baclofen of alcohol deprivation effect in Sardinian alcohol-preferring (sP) rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.500811

Effect of baclofen on alcohol and sucrose self-administration in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.500811

GABA(B) receptor agonists reduce operant ethanol self-administration and enhance ethanol sedation in C57BL/6J mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.500811

Baclofen-induced reduction of alcohol reinforcement in alcohol-preferring rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.500811

The GABA(B) receptor allosteric modulator CGP7930, like baclofen, reduces operant self-administration of ethanol in alcohol-preferring rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.500811

The gamma-aminobutyric acid-B receptor agonist baclofen attenuates responding for ethanol in ethanol-dependent rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.500811

Effects of baclofen and nitrendipine on ethanol withdrawal responses in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.500811

The amygdala regulates the antianxiety sensitization effect of flumazenil during repeated chronic ethanol or repeated stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.500811

The effects of GABAB ligands on alcohol withdrawal in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.500811

Ethanol and sucrose seeking and consumption following repeated administration of the GABA(B) agonist baclofen in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.500811

Rapid suppression of alcohol withdrawal syndrome by baclofen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.500811

Baclofen in the treatment of alcohol withdrawal syndrome: a comparative study vs diazepam

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.500811

Baclofen for alcohol dependence: a preliminary open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.500811

Renin and aldosterone but not the natriuretic peptide correlate with obsessive craving in medium-term abstinent alcohol-dependent patients: a longitudinal study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.500811

Insulin but not insulin growth factor-1 correlates with craving in currently drinking alcohol-dependent patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.500811

Baclofen efficacy in reducing alcohol craving and intake: a preliminary double-blind randomized controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.500811

Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.500811

Acute interaction of baclofen in combination with alcohol in heavy social drinkers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.500811

An overview of medications for the treatment of alcohol withdrawal and alcohol dependence with an emphasis on the use of older and newer anticonvulsants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.500811

Progress in the development of topiramate for treating alcohol dependence: from a hypothesis to a proof-of-concept study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.500811

Effects of topiramate on ethanol and saccharin consumption and preferences in C57BL/6J mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.500811

Topiramate reduces ethanol consumption by C57BL/6 mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.500811

Topiramate (Topamax) reduces conditioned abstinence behaviours and handling-induced convulsions (HIC) after chronic administration of alcohol in Swiss-Webster mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.500811

Topiramate moderately reduces the motivation to consume alcohol and has a marked antidepressant effect in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.500811

Effects of topiramate on urge to drink and the subjective effects of alcohol: a preliminary laboratory study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.500811

Oral topiramate for treatment of alcohol dependence: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.500811

Effects of topiramate in the treatment of alcohol dependence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.500811

Topiramate for treating alcohol dependence: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.500811

Improvement of physical health and quality of life of alcohol-dependent individuals with topiramate treatment: US multisite randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.500811

Comparing topiramate with naltrexone in the treatment of alcohol dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.500811

Using topiramate or naltrexone for the treatment of alcohol-dependent patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.500811

Efficacy of a combination of flumazenil and gabapentin in the treatment of alcohol dependence: relationship to alcohol withdrawal symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.500811

Treatment of alcohol withdrawal with gabapentin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.500811

A randomized, open-label, controlled trial of gabapentin and phenobarbital in the treatment of alcohol withdrawal

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.500811

Gabapentin's acute effect on mood profile -- a controlled study on patients with alcohol withdrawal.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.500811

A double-blind trial of gabapentin versus lorazepam in the treatment of alcohol withdrawal

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.500811

An open trial of gabapentin in acute alcohol withdrawal using an oral loading protocol

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.500811

Cellular and behavioral interactions of gabapentin with alcohol dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.500811

Efficacy and safety of pregabalin in alcohol dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.500811

Polymorphisms in the mitochondrial aldehyde dehydrogenase gene (Aldh2) determine peak blood acetaldehyde levels and voluntary ethanol consumption in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.500811

The Fawn-Hooded (FH/Wjd) rat: a genetic animal model of comorbid depression and alcoholism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.500811

Daidzin and daidzein suppress free-choice ethanol intake by Syrian golden hamsters

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.500811

Daidzin: a potent, selective inhibitor of human mitochondrial aldehyde dehydrogenase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.500811

Daidzin suppresses ethanol consumption by Syrian golden hamsters without blocking acetaldehyde metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.500811

Daidzin inhibits mitochondrial aldehyde dehydrogenase and suppresses ethanol intake of Syrian golden hamsters

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.500811

An extract of the Chinese herbal root kudzu reduces alcohol drinking by heavy drinkers in a naturalistic setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.500811

Suppression of heavy drinking and alcohol seeking by a selective ALDH-2 inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.500811

Are anandamide and cannabinoid receptors involved in ethanol tolerance? A review of the evidence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.500811

Endocannabinoid system and alcohol addiction: pharmacological studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.500811

CB1 receptor blockade decreases ethanol intake and associated neurochemical changes in fawn-hooded rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.500811

Selective inhibition of sucrose and ethanol intake by SR 141716, an antagonist of central cannabinoid (CB1) receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.500811

Suppressing effect of the cannabinoid CB1 receptor antagonist, SR147778, on alcohol intake and motivational properties of alcohol in alcohol-preferring sP rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.500811

Ethanol induces higher BEC in CB1 cannabinoid receptor knockout mice while decreasing ethanol preference

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.500811

Rimonabant (SR141716) has no effect on alcohol self-administration or endocrine measures in nontreatment-seeking heavy alcohol drinkers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.500811

Varenicline reduces alcohol self-administration in heavy-drinking smokers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.500811

Metabotropic glutamate receptor ligands as potential therapeutics for addiction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.500811

alpha1-noradrenergic receptor antagonism blocks dependence-induced increases in responding for ethanol

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.500811

A pilot trial of the alpha-1 adrenergic antagonist, prazosin, for alcohol dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.500811

Interaction between CRHR1 gene and stressful life events predicts adolescent heavy alcohol use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.500811

Variation at the rat Crhr1 locus and sensitivity to relapse into alcohol seeking induced by environmental stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.500811

Hypothalamic-pituitary-adrenocortical axis activity: a target of pharmacological anticraving treatment?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.500811

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.500811

Vivitrex, an injectable, extended-release formulation of naltrexone, provides pharmacokinetic and pharmacodynamic evidence of efficacy for 1 month in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.500811

10.1517/14728214.2010.500811

21 January 2018

Identifiers

DOI

1 reference

22 August 2017

1 reference

PubMed ID

20560783